Personalized Treatment Of Advanced Her2-Negative Gastric Or Gastroesophageal Junction Cancer

Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer

Touch Medical Media Services

Targeted treatment for gastric cancer beyond HER2

Taking Aim at GI Cancers With Personalized HER2 and Other Molecularly Targeted Therapies

PeerView Oncology

Personalizing Gastric Cancer Care With HER2-Targeted and Other Novel Therapies

PeerView Oncology

Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma

GASTHER2: trastuzumab for advanced gastric cancer

HER2+ targeted therapy for locally advanced gastric cancer and cardioesophageal junction

НМИЦ онкологии им. Н.Н. Петрова

For Pharmacists: Evolution of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma

ARMANI: Ramucirumab Plus Paclitaxel as Switch Maintenance for Advanced HER2-Negative Gastric Cancer

GI Oncology Now

Optimizing Precision Medicine in Gastric Cancer Care

PeerView Oncology

HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

PeerView Oncology

PANTHERA: pembrolizumab, trastuzumab, and chemotherapy in HER2+ advanced gastric cancer

TTX-030, budigalimab, and FOLFOX combination therapy in advanced or metastatic gastric/GEJ cancer

Optimizing Novel HER2-Targeted Therapies and Other Agents in Gastric Cancer Care

PeerView Oncology

Advances in HER2-targeted therapies for gastric cancer

Consolidative radiotherapy for oligometastatic HER2-negative esophageal and gastric adenocarcinoma.

Algorithms for Management of Locally-advanced and Metastatic Gastric & GE Junction Adenocarcinomas

Metastatic gastric cancer: Indications and impact of targeting the HER2 pathway?

Advanced gastric and gastroesophageal cancer in Asia

COR2ED The Heart of Medical Education

MAHOGANY: margetuximab in gastric cancer